---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-052167"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-06-12T23:59:59+00:00"
generated_at: "2026-06-01T04:55:47.928616+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharmaceuticals receives FDA orphan drug designation for tafenoquine to treat acute babesiosis

## Summary
- FDA granted orphan drug designation for tafenoquine for acute babesiosis; company qualifies for market exclusivity, tax credits, and exemption from certain FDA filing fees.
- Company entered agreement with Tufts Medical Center for first clinical trial in human babesiosis patients; recruitment starts June 13, 2024, with at least 24 hospitalized patients.
- Babesiosis is transmitted by deer ticks; up to 47,600 of ~476,000 annual Lyme patients may be co-infected with Babesia.

## SEC filing metadata
- accession: 0001213900-24-052167
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-06-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024052167/0001213900-24-052167-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024052167/ea020775201-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-052167
- JSON: https://secwatch.observer/filing/0001213900-24-052167.json
- Plain text: https://secwatch.observer/filing/0001213900-24-052167.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.